{"id":21,"date":"2008-05-21T09:58:24","date_gmt":"2008-05-21T14:58:24","guid":{"rendered":"http:\/\/blogs.nejm.org\/pov\/hiv-id-observations\/index.php\/2008\/05\/21\/when-expert-clinicians-disagree\/"},"modified":"2008-05-21T09:58:24","modified_gmt":"2008-05-21T14:58:24","slug":"when-expert-clinicians-disagree","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/when-expert-clinicians-disagree\/2008\/05\/21\/","title":{"rendered":"When Expert Clinicians Disagree"},"content":{"rendered":"<p>Periodically, in <em>AIDS Clinical Care, <\/em>we publish a case in the &#8220;Antiretroviral Rounds&#8221; section and ask two clinical experts in our field how they would manage such a patient. The most recent case elicited responses that were 180 degrees different.<\/p>\n<p>(This is exactly what we&#8217;re after, by the way &#8212; why present a case in which everyone would do the same thing?)<\/p>\n<p>The <a href=\"http:\/\/aids-clinical-care.jwatch.org\/cgi\/content\/full\/2008\/505\/1\">full details of the case <\/a>are on the <em>AIDS Clinical Care<\/em> web site, but in brief: A 50-year-old man with longstanding HIV was admitted to the hospital with gallstone pancreatitis, during which time he experienced virologic rebound since he couldn&#8217;t take anything by mouth. Athough for years he&#8217;d been mostly virologically suppressed &#8212; with some values between 50 and 500 cop\/mL &#8212; on a regimen of TDF\/FTC and boosted fosamprenavir, the resistance genotype sent after viral rebound showed extensive triple-class drug resistance. Resuming therapy after his recovery led to a drop in the viral load again to undetectable. Should this patient change treatment?<\/p>\n<p>One of our respondents (Joe Gathe) said &#8212; confidently &#8212; to stay the course, no change; the other (Rick Elion) said &#8212; assuredly &#8212; to change to a completely new regimen. Is it possible that both are right? After all, both these guys have extensive clinical experience in HIV care and research; are widely respected in the field; and were able to cite excellent reasons defending their management decisions. These are the kind of doctors you&#8217;d send a family member or friend to if he\/she had HIV.<\/p>\n<p>So I&#8217;ll go out on a limb and say yes, both were right &#8212; but for the non-clinician, the fact that there are such different ways to manage one problem can be unsettling.  Indeed, our executive editor (a non-MD) said she felt &#8220;uncomfortable&#8221; with these vastly different approaches to treatment.<\/p>\n<p>Needless to say, the case is drawn from real life, but before I divulge how it was managed, I&#8217;d be interested to hear what others would do.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Periodically, in AIDS Clinical Care, we publish a case in the &#8220;Antiretroviral Rounds&#8221; section and ask two clinical experts in our field how they would manage such a patient. The most recent case elicited responses that were 180 degrees different. (This is exactly what we&#8217;re after, by the way &#8212; why present a case in [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2,3,4,5,8],"tags":[76,77,191,423,948],"class_list":["post-21","post","type-post","status-publish","format-standard","hentry","category-antiretroviral-rounds","category-health-care","category-hiv","category-infectious-diseases","category-patient-care","tag-antiretroviral-rounds","tag-antiretroviral-therapy","tag-clinical-care","tag-hiv","tag-triple-class-resistance"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/21","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/comments?post=21"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/21\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/media?parent=21"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/categories?post=21"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/tags?post=21"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}